Clinical trials: Skin Diseases, Papulosquamous
Oral Lichen Planus, Vitamin D Deficiency
Vitamin D Deficiency As a Risk Factor for the Development and Malignant Transformation of Oral Lichen Planus
To examine how a lack of vitamin D may increase the risk of developing oral lichen planus and its malignant progression while accounting for sex, food habits, sunlight, socioeconomic level, and psychological variables.
- Trial name
- NCT06033105
- Testing
- ELISA
- Where
- Egypt
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Fayoum University
Psoriasis
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to assess the efficacy and safety of repeated administration of adalimumab in adult Japanese subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00338754
- Testing
- Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks
- Where
- 8 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Abbott
Psoriasis
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation…
- Trial name
- IMMagine (NCT05959070)
- Where
- 16 sites in Belgium, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriasis (PsO)
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: How safe is taking ESK-001 long-term in people with moderate to…
- Conditions
- Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
- Trial name
- ONWARD3 (NCT06846541)
- Testing
- Open-Label Envudeucitinib, Blinded Envudeucitinib
- Where
- 268 sites in United States, Australia and 14 more
- Volunteers
- 1,680 people
- Sponsor
- Alumis Inc
Psoriasis
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in…
- Trial name
- NCT06477237
- Testing
- HB0017 Q4W, HB0017 Q8W
- Where
- 44 sites in China
- Volunteers
- 408 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT03022045
- Testing
- risankizumab
- Where
- 9 sites in Japan
- Volunteers
- 18 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
- Trial name
- NCT03179605
- Testing
- DFD06
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Primus Pharmaceuticals
Plaque Psoriasis
The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
To describe the response of etanercept after adalimumab has failed to produce a satisfactory response in moderate to severe plaque psoriasis.
- Trial name
- NCT00833729
- Testing
- etanercept
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dermatrials Research
Lichen Planus, Oral
Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus
This study will compare two treatments for oral lichen planus - hydroxychloroquine (Plaquenil) tablets and clobetasol oral rinse.
- Trial name
- NCT00102557
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Psoriasis
Use of Serum M2BP and MSUS to Predict Arthritis in Psoriatic Patients
Aims of the study: 1. Measurement of serum level of Mac 2 binding protein among patients with psoriasis, psoriatic arthritis and subclinical psoriatic arthritis compared with healthy individuals. 2.
- Trial name
- NCT04435730
- Testing
- serum level of Mac 2 binding protein, musculoskeletal ultrasound
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assiut University
Psoriasis
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis
The clinical objective of this study was to determine the effect of BIRB 796 BS on pharmacodynamic markers of psoriasis as a measure of efficacy, to determine the population pharmacokinetics of BIRB 796 BS and to determine the…
- Trial name
- NCT02209753
- Testing
- BIRB 796 BS, low dose, BIRB 796 BS, medium dose 1, BIRB 796 BS, medium dose 2
- Volunteers
- 182 people
- Sponsor
- Boehringer Ingelheim
Inflammatory Bowel Diseases, Ulcerative Colitis
Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, Arthritis, Rheumatoid
- Trial name
- MISTIC (NCT04191395)
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-2 (NCT03611751)
- Testing
- BMS-986165, Apremilast
- Where
- 205 sites in United States, Australia and 14 more
- Volunteers
- 1,020 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
- Trial name
- NCT06952465
- Testing
- Deucravacitinib, Any biologic treatment for psoriasis
- Where
- 2 sites in Japan
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis Vulgaris, Seborrheic Dermatitis
Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients
A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study.
- Conditions
- Psoriasis Vulgaris, Seborrheic Dermatitis, Microbial Colonization
- Trial name
- NCT03807453
- Testing
- Microbiota
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Medeniyet University
Psoriatic Arthritis, Psoriatic Nail
Sonographic Analysis of Nails in Psoriatic Arthritis and Healthy Controls
This study aims to identify the nail ultrasonography (NUSG) properties in patients with psoriatic arthritis (PsA) and healthy controls by a participant-based evaluation; to assess feasibility, reliability, and discriminative…
- Trial name
- NUSGI (NCT04718428)
- Testing
- Nail Ultrasonography
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Marmara University
Lichen Planus, Oral, Lichen Planus of Vulva
Clinical and Molecular Correlates of Response to First Line Treatment in Lichen Planus
Lichen planus is a common inflammatory (swelling and pain of tissue) disease in the general population that affects mostly the mouth although skin and genital areas can also be affected.
- Trial name
- NCT05330572
- Testing
- No interventions were administered to the patients as a part of this study.
- Where
- 2 sites in United Kingdom
- Volunteers
- 110 people
- Sponsor
- University of Aberdeen
Psoriatic Arthritis, Spondylitis
Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement
To evaluate the efficacy of Tofacitinib in reducing inflammation in the sacroiliac joints and spine on magnetic resonance imaging (MRI) in patients with active Psoriatic Arthritis (PsA) with axial Involvement (BASDAI [Bath…
- Conditions
- Psoriatic Arthritis, Spondylitis, Sacroilitis
- Trial name
- PASTOR (NCT04062695)
- Testing
- Tofacitinib 5 MG Oral Tablet [Xeljanz]
- Where
- 19 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.